Celecoxib for the Prevention of Sporadic Colorectal Adenomas

20061,036 citationsJournal Articlebronze Open Access

Authors

Monica M. Bertagnolli · Brigham and Women's Hospital

Craig Eagle · Pfizer (United States)

Ann G. Zauber · Memorial Sloan Kettering Cancer Center

Mark Redston · Brigham and Women's Hospital

Scott D. Solomon · Brigham and Women's Hospital

KyungMann Kim · University of Wisconsin–Madison

Jie Tang

Abstract

These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication. (ClinicalTrials.gov number, NCT00005094 [ClinicalTrials.gov].).

Topics & Keywords

Inflammatory mediators and NSAID effects Helicobacter pylori-related gastroenterology studies Veterinary medicine and infectious diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 9, pp. 873-884

DOI: 10.1056/nejmoa061355

Field-Weighted Citation Impact: 81.65